Relapsed/Refractory Mantle Cell LymphomaPhase 2ZUMA-2NCT04880434
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
A Phase 2 study testing Fludarabine, Cyclophosphamide and Brexucabtagene autoleucel in people with Relapsed/Refractory Mantle Cell Lymphoma, run by Kite, A Gilead Company at 40 sites in 6 countries.
Trial summary
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) who have not previously received Bruton's tyrosine kinase inhibitor (BTKi). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Relapsed/Refractory Mantle Cell Lymphoma
- What is being tested?
- Fludarabine, Cyclophosphamide and Brexucabtagene autoleucel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 95 participants
- Where
- 40 sitesin 6 countries
- Study dates
- 23 Apr 2021to 17 Jun 2025
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Up to 5 prior regimens for mantle cell lymphoma (MCL). Prior therapy must have included anthracycline- or bendamustine-containing chemotherapy and anti-cluster of differentiation 20 (CD20) monoclonal antibody therapy. Individuals must not have received prior therapy with a Bruton's tyrosine kinase inhibitor (BTKi).
- At least 1 measurable lesion
- Platelet count ≥ 75,000/μL
- Creatinine clearance (as estimated by Cockcroft Gault) ≥ to 60 cc/min
- Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition (MUGA), and no clinically significant electrocardiogram (ECG) findings
- Baseline oxygen saturation > 92% on room air
Who cannot join
- Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAG positive) or anti-hepatitis C virus (HCV) positive. Individuals with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing
- History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or any autoimmune disease with central nervous system (CNS) involvement
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
40 sites in 6 countries.
40 sites in 6 countries
United States23 sites
Emory University
Atlanta, Georgia, 30322
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
University of Chicago
Chicago, Illinois, 60637
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, 44195
Ohio State University
Columbus, Ohio, 43220
Baylor Cancer Hospital
Dallas, Texas, 75246
Sarah Cannon- Denver
Denver, Colorado, 80218
Karmanos Cancer Institute
Detroit, Michigan, 48201
Duke University
Durham, North Carolina, 27710
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234
Hackensack University Medical Center
Hackensack, New Jersey, 07601
MD Anderson Cancer Center
Houston, Texas, 77030
Loyola University Medical Center
Maywood, Illinois, 60153
University of Miami
Miami, Florida, 33136
Sarah Cannon - Tenessee
Nashville, Tennessee, 37203
Vanderbilt University
Nashville, Tennessee, 37232
Stanford University
Palo Alto, California, 94305
Advocate Aurora Health - Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
University of Rochester
Rochester, New York, 14642
University California Los Angeles (UCLA)
Santa Monica, California, 90404
Swedish Cancer Institute
Seattle, Washington, 98104
Moffitt Cancer Center
Tampa, Florida, 33612
France5 sites
CHU de Montpellier
Montpellier, 34295
Hospital Saint Louis
Paris, 75010
Hopital Haut-Leveque
Pessac, 44035
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495
CHU de Rennes
Rennes, 35033
Germany3 sites
Johannes Gutenberg University Hospital-University Mainz
Mainz, 55101
Munich University of Technology-Medical Faculty- Ethics Committee
München, 81377
Universitaetsklinikum Wuerzburg
Würzburg, 97080
Netherlands3 sites
Academisch Medisch Centrum
Amsterdam, 1100
University Medical Center Groningen
Groningen, 9700 RB
Erasmus MC
Rotterdam, 3015 CE
Spain3 sites
Hospital Universitari Vall D'Hebron
Barcelona, 08035
Hospital Clinic Barcelona
Barcelona
Hospital Universitario de Salamanca
Salamanca, 37007
United Kingdom3 sites
Queen Elizabeth University Hospital
Glasgow, G51 4TF
Kings College Hospital
London, SE5 9RS
Manchester Royal Infirmary
Manchester, M13 9WL
About this study
Official title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) who have not previously received Bruton's tyrosine kinase inhibitor (BTKi).
Read the detailed description
Study KTE-C19-102 (NCT02601313) enrolled participants with r/r MCL who had been treated with up to 5 prior regimens, including a BTKi, in Cohorts 1 and 2. To fulfill an FDA postmarketing requirement, Cohort 3 is added to the study. Cohort 3 includes participants with r/r MCL who have been treated with up to five prior regimens but have not received prior therapy with a BTKi.
The final analysis for Cohorts 1 and 2 has been completed. Data for Cohort 3 are analyzed separately. Therefore, this separate registration is only for Cohort 3.
After the end of KTE-C19-102, subjects who received an infusion of anti-CD19 CAR T cells will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).
- Conditions
- Relapsed/Refractory Mantle Cell Lymphoma
- Being tested
- Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel
- Medical subject headings
- Lymphoma, Mantle-Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FludarabineDrug
Administered as intravenous infusion
CyclophosphamideDrug
Administered as intravenous infusion
Brexucabtagene autoleucelBiological
Also called KTE-X19, Tecartus™
Administered as intravenous infusion
| Study group | Role | What they receive |
|---|---|---|
| Brexucabtagene autoleucel (KTE-X19) | Experimental | Participants with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have been treated with up to 5 prior regimens but have not received prior therapy with a Bruton's tyrosine kinase inhibitor (BTKi) will receive the following treatment during the study:
* A conditioning chemotherapy regimen of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day for 3 days (Day -5 to Day -3).
* A single infusion of brexucabtagene autoleucel at a target dose of 2×10^6 anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) transduced autologous T cells/kg, with a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells for participants > 100 kg on Day 0. Receives: Drug: Fludarabine; Drug: Cyclophosphamide; Biological: Brexucabtagene autoleucel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 3
OR: complete metabolic response (CMR),complete radiological response (CRR), partial MR response (PMR),partial RR(PRR).CMR:score 1(no uptake above background)/2(uptake ≤mediastinum)/3(uptake >mediastinum but ≤liver) with/without a residual mass on positron emission tomography 5-point scale;no new lesions.CRR:target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter of lesion (LDi);no extralymphatic sites of disease;absent non-measured lesion(NMLs);organ enlargement regress to normal;no new sites;bone marrow normal by morphology. PMR:score 4(uptake moderately >liver)/5(uptake markedly >liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥50% decrease in sum of the product of the diameters(SPD) of up to 6 target measurable nodes and extra-nodal sites;absent/normal, regressed, but no increase of NMLs;spleen regressed by >50% in length beyond normal.
Measured: Up to 4 years
Secondary outcomes (18)
Duration of Response (DOR) Per the Lugano Classification According to IRRC in Cohort 3
DOR: time from the first OR to progressive disease (PD)/death. It was determined using Kaplan-Meier (KM) estimates. PD: score 4 (uptake moderately > liver)/ 5 (uptake markedly >liver and/or new lesions) with an increase in intensity of uptake from baseline; new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma at interim/EOT assessment; new FDG-avid foci consistent with lymphoma rather than another etiology; new/recurrent FDG-avid foci in bone marrow; an individual node/lesion must be abnormal with: LDi > 1.5 cm, increase by ≥ 50% from cross-product of LDi and perpendicular diameter (PPD) nadir, increase in LDi or shortest axis perpendicular to the LDi from nadir, the splenic length must increase by > 50% of the extent of its prior increase beyond baseline. If no prior splenomegaly, the increase must be ≥ 2 cm from baseline; new/recurrent splenomegaly; new or clear progression of pre-existing NMLs; new lesion; new/recurrent bone marrow involvement.
Measured: Up to 4 years
Percentage of Participants With Best Objective Response (BOR) as Per Investigator Assessment Determined by Lugano Classification in Cohort 3
BOR consisted of complete response (CR), partial response (PR), stable disease (SD), PD, not done and not evaluable (NE). CR=CMR/CRR and PR=PMR/PRR were defined in Outcome Measure (OM) 1. SD/no metabolic response (NMR): a score 4 (uptake moderately greater than (>) liver) or 5 (uptake markedly >liver and/ or new lesions) with no significant change in FDG uptake compared to baseline (screening), at an interim time point or end of treatment; no new sites of disease should be observed. PD was defined in OM 2. Not done: no assessment at the time of analysis. Clopper-Pearson method was used for OM analysis. Percentages were rounded off.
Measured: Up to 4 years
Percentage of Participants With Objective Response (OR) as Per Investigator Assessment Determined by Lugano Classification in Cohort 3
OR was defined in OM #1. Percentages were rounded-off.
Measured: Up to 4 years
Progression Free Survival (PFS) Per the Lugano Classification According to IRRC in Cohort 3
PFS was defined as the time from brexucabtagene autoleucel infusion date to the date of PD or death from any cause. PD was defined in OM #2. Kaplan-Meier (KM) estimates were used for analysis.
Measured: Up to 4 years
Overall Survival (OS)
OS was defined as the time from brexucabtagene autoleucel infusion to the date of death from any cause. KM estimates were used for analysis.
Measured: Up to 4 years
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participants. The event did not necessarily have a relationship with study treatment. AE included worsening of a pre-existing medical condition. Worsening indicated that the pre-existing medical condition had increased in severity, frequency, and/or duration or had an association with a worse outcome. A pre-existing condition that had not worsened during the study or involved an intervention such as elective cosmetic surgery or a medical procedure while on study, was not considered an AE. TEAE was defined as any AE with onset on or after the start of treatment.
Measured: Up to 3 years
Percentage of Participants With Increase in Post-brexucabtagene Autoleucel Infusion Hematology Toxicity Values by Worst Toxicity Grade
Laboratory results were graded according to National Cancer Institute Common Terminology Criteria for Adverse Event (CTCAE) version 4.03. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 life-threatening. Percentages were rounded-off.
Measured: Up to 3 years
Percentage of Participants With Increase in Post-brexucabtagene Autoleucel Infusion Chemistry Toxicity Values by Worst Toxicity Grade
Laboratory results were graded according to National Cancer Institute CTCAE version 4.03. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 life-threatening. Percentages were rounded-off.
Measured: Up to 3 years
Percentage of Participants With Decrease in Post-brexucabtagene Autoleucel Infusion Hematology Toxicity Values by Worst Toxicity Grade
Laboratory results were graded according to National Cancer Institute CTCAE version 4.03. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 life-threatening. Percentages were rounded-off.
Measured: Up to 3 years
Percentage of Participants With Decrease in Post-brexucabtagene Autoleucel Infusion Chemistry Toxicity Values by Worst Toxicity Grade
Laboratory results were graded according to National Cancer Institute CTCAE version 4.03. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 life-threatening. Percentages were rounded-off.
Measured: Up to 3 years
Percentage of Participants With Anti-CD19 CAR Antibodies
Measured: Baseline up to Month 3
Maximum Number of CAR T Cells Measured Post-infusion
Measured: Up to Month 36
Peak Serum Levels of C-Reactive Protein (CRP) in Blood
Peak was defined as the maximum post-baseline level of the cytokine.
Measured: Baseline up to Week 4
Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Granzyme B, Interferon-gamma (IFN-γ), Interleukin (IL)-1 Receptor Antagonist (RA), IL-2, IL-6, IL-7, IL-8, IL-10, IL-15 and Tumor Necrosis Factor (TNF)-α in Blood
Peak was defined as the maximum post-baseline level of the cytokine.
Measured: Baseline up to Week 4
Peak Serum Levels of Ferritin, Intercellular Adhesion Molecule (ICAM)-1, IL-2 Receptor Alpha (Rα), Perforin and Vascular Cell Adhesion Molecule (VCAM)-1 in Blood
Peak was defined as the maximum post-baseline level of the cytokine.
Measured: Baseline up to Week 4
Percentage of Participants With European Quality of Life-5 Dimensions (EQ-5D) Scale Score at Different Timepoints
The European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) was a participant-answered questionnaire scoring 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each dimension the participant was asked for a three-level assessment of their health on the current day: "no problems" (1), "some problems" (2), "extreme problems" (3). EQ-5D health states, defined by the EQ-5D descriptive system, were converted into a single summary index by applying a formula that attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. Percentage of participants with each scale score for all 5 dimensions are reported. Percentages were rounded-off.
Measured: Day 0, Month 18 and Month 24
EQ-5D Visual Analogue Scale (VAS) Score at Different Timepoints
EQ-5D was a standardized participant completed questionnaire that measures health-related quality of life and translated the score into an index value or utility score. EQ-5D-consisted of two components: a health state profile and an optional visual analogue scale (VAS). The EQ-5D-VAS recorded the participant's self-rated health on a vertical visual analogue scale, where the endpoints were labelled 'The best health you can imagine' and 'The worst health you can imagine'. EQ-5D-VAS: range 0 to 100. A higher score indicated better self-reported health status.
Measured: Day 0, Month 18 and Month 24
Percentage of Participants With Deterioration Scores From Screening in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30
EORTC QLQ-C30 included functional scales (physical, role, cognitive, emotional, and social), global health status/quality of life (QoL) scale, symptom scales (fatigue, pain, nausea/vomiting), and single items scales (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions use 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores are averaged, transformed to 0-100 scale. Higher scores for functional scales and for the global health status/QoL scale indicate a higher level of functioning and a better health-related QoL, whereas higher scores in symptom scales represent a higher level of symptoms. Deterioration of score was defined as worsened by at least 1 level from screening. Participants with answer "Yes" to the EORTC functional scale questionnaire were reported.
Measured: Screening Day -28 to Leukapheresis (Day -5), Day 0, Month 18 and Month 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2021
- Study start23 Apr 2021
- Primary completion17 Jun 2025
- Study completion17 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (60)Papers the sponsor has linked to this study.
- Other trials for Relapsed/Refractory Mantle Cell LymphomaStudies of the same condition, open and under way.
- More trials run by Kite, A Gilead CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kite, A Gilead Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kite Study Director, Study director, Kite, A Gilead Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04880434
- Sponsor's protocol ID
- KTE-C19-102 (Cohort 3)
- Other IDs
- 2015-005008-27, 2023-506641-35, 2023, 2015
- Acronym
- ZUMA-2
- Status last verified
- Jul 2026
- First submitted
- 30 Apr 2021
- Last updated
- 18 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified external researchers may request IPD for this study. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Publications
Salles G, Chen JMH, Zhang I, Kerbauy F, Wu JJ, Wade SW, Nunes A, Feng C, Kloos I, Peng W, Snider JT, Maciel D, Chan K, Keeping S, Shah B. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Adv Ther. 2024 May;41(5):1938-1952. doi: 10.1007/s12325-024-02822-z. Epub 2024 Mar 18.
PubMed 38494543Goy A, Jacobson CA, Flinn IW, Hill BT, Weng W, Mountjoy L, et al. Outcomes of patients with relapsed/refractory mantle cell lymphoma (r/r MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study. Blood 2023; 142 (Supplement 1): 106.
Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, Gastinne T, Lamy T, Roussel M, Bouabdallah K, Beauvais D, Cartron G, Bay JO, Blaise D, Rubio MT, Mohty M, Le Bras F, Casasnovas O, Guy J, Guidez S, Llorente CC, Hermine O, La Rochelle LD, Carras S, Guffroy B, Caillat-Zucman S, Houot R, Le Gouill S. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024 Nov 1;109(11):3745-3750. doi: 10.3324/haematol.2023.284786. No abstract available.
PubMed 38899352Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2024 Jan;65(1):14-25. doi: 10.1080/10428194.2023.2268228. Epub 2024 Jan 10.
PubMed 37840282Kilgore KM, Chan PK, Teigland C, Wade SW, Mohammadi I. Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States. J Manag Care Spec Pharm. 2025 Mar;31(3):262-276. doi: 10.18553/jmcp.2025.31.3.262.
PubMed 40021461Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann BN, Serroukh Y, Blaise D, Beelen DW, Solano C, Itala-Remes M, van Meerten T, Choi G, Schmidt SAC, Kroger N, Byrne J, Tudesq JJ, Ossami Saidy A, Nunes A, Siddiqi R, Baro E, Zheng D, Kloos I, Dreger P, Sureda A, Glass B, Dietrich S. Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. Blood Cancer Discov. 2025 May 5;6(3):182-190. doi: 10.1158/2643-3230.BCD-24-0178.
PubMed 39913291Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann B, et al. A propensity score-matched analysis on outcomes of brexucabtagene autoleucel from ZUMA-2 and allogeneic stem cell transplantation from ebmt database in relapsed/refractory post-btki mantle cell lymphoma. The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O008). Bone Marrow Transplant 2024; 59 (Suppl 1): 12-19; Poster O008.
Locke F, Hu ZH, Gerson J, Frank MJ, Budde LE, Wang M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed or refractory (r/r) mantle cell lymphoma (mcl) in the United States (US). HemaSphere 2022; 6():1336-1337; Poster 1454.
Maglinte GA, Simons CL, Wang M, Wade SW, Brown M, Petersohn S, et al. Cost-effectiveness of KTE-X19 CAR-T therapy following bruton tyrosine kinase inhibitor treatment for relapsed/refractory mantle cell lymphoma in England. The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P182. Bone Marrow Transplant 2021;56 (Suppl 1): 184-335; Poster 014.
Meerten T, Kersten MJ, Iacoboni G, Hess G, Mutsaers P, García-Sancho AM, et al. Primary analysis of ZUMA-2 cohort 3: brexucabtagene autoleucel (brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who were naive to bruton tyrosine kinase inhibitors (BTKi). Blood 2024; 144 (Supplement 1): 748.
Oluwole OO, Reagan PM, Miklos DB, Locke FL, Goy A, Jacobson CA, et al. Assessment of early intervention strategies for management of cytokine release syndrome and neurologic events after brexucabtagene autoleucel (brexu-cel) treatment in patients with relapsed or refractory mantle cell lymphoma (r/r MCL) in ZUMA-2. Blood 2023; 142 (Supplement 1): 2120.
Adhikary S, Damico Khalid R, Dreyling M, Galal A, Garcia-Sancho A, Gine E, et al. Two-Year Update of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Had Not Received Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy [Poster]. American Society of Hematology - 67th Annual Meeting 2025.
Beitinjaneh A, Chang M, Damico Khalid R, Flinn I, Forcade E, Goy A, et al. Résultats à cinq ans des patients (pts) atteints d'un lymphome à cellules du manteau (LCM) en rechute ou réfractaire (R/R) traités par brexucabtagene autoleucel (brexu-cel) dans les cohortes 1 et 2 (C1&C2) de ZUMA-2 Five-Year Outcomes of Patients (pts) With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL) Treated with Brexucabtagene Autoleucel (brexu-Cel) in ZUMA-2 Cohorts 1 and 2 (c1&c2) [Poster]. Societe Francaise d'Hematologie - 2025 Annual Congress 2025.
Chen JMH, Zhang I, Wu JJ, et al. Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi) [Poster]. American Society of Hematology - 65th Annual Meeting 2023.
Chen JMH, Zhang I, Wu JJ, Wade SW, Nunes A, Peng W, et al. Matching-adjusted indirect comparison (maic) of brexucabtagene autoleucel (brexu-cel) and pirtobrutinib in patients with relapsed/refractory (r/r) mantle cell lymphoma (MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (cBTKi). Blood 2023; 142 (Supplement 1): 5136.